Stockpolly
Search
Delisting risk
DCOY · NASDAQ · Biotechnology

Decoy Therapeutics (DCOY)

Developer of peptide-conjugate antivirals against shared viral fusion machinery.

$2.82
Pre-market−0.17 (−5.69%)
At close$2.99(−2.29%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000900
Gross profit000000000−900
312111211123
Research & development100000000011
112111211021
General & administrative112111211021
Operating income−3−1−2−1−1−1−2−1−1−9−2−3
000000000000
Interest income000000000000
Other non-operating income000000000000
Income before tax−2−1−2−1−1−1−2−1−1−9−2−2
Net income from continuing operations−2−1−2−1−1−1−2−1−1−9−2−2
Net income−2−1−2−1−1−1−2−1−1−9−2−2
EPS, basic−$78.09−$26.87−$49.07−$35.59−$11.38−$15.24−$15.41−$6.77−$1.81−$18.64−$4.18−$4.46
EPS, diluted−$78.09−$26.87−$49.07−$35.59−$11.38−$15.24−$15.41−$6.77−$1.81−$18.64−$4.18−$4.46
Weighted average shares, basic000000000011
Weighted average shares, diluted000000000011
EBITDA−3−1−2−1−1−1−2−1−1−9−2−2
Depreciation & amortization000000000000
EBIT−3−1−2−1−1−1−2−1−1−9−2−2